1. Home
  2. XELB vs RNAZ Comparison

XELB vs RNAZ Comparison

Compare XELB & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

N/A

Current Price

$1.47

Market Cap

10.6M

Sector

Miscellaneous

ML Signal

N/A

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

N/A

Current Price

$9.54

Market Cap

8.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XELB
RNAZ
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
8.5M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
XELB
RNAZ
Price
$1.47
$9.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$280.00
AVG Volume (30 Days)
38.7K
18.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$83.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.22
52 Week High
$4.52
$20.99

Technical Indicators

Market Signals
Indicator
XELB
RNAZ
Relative Strength Index (RSI) 44.21 50.84
Support Level $1.38 $9.67
Resistance Level $1.60 $11.79
Average True Range (ATR) 0.20 0.78
MACD -0.06 -0.06
Stochastic Oscillator 6.49 56.67

Price Performance

Historical Comparison
XELB
RNAZ

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: